<DOC>
	<DOCNO>NCT01667211</DOCNO>
	<brief_summary>Using albumin-bound paclitaxel nedaplatin advance recurrent metastasis cervical cancer , evaluate efficacy toxic reaction .</brief_summary>
	<brief_title>Clinical Study Albumin-bound Paclitaxel Plus Nedaplatin Cervical Cancer</brief_title>
	<detailed_description>Albumin-bound paclitaxel novel , solvent-free , albumin-bound nanoparticle form paclitaxel design avoid problem associated solvent use Taxol . And albumin-bound paclitaxel characterize high tolerate dos great efficacy , great concentration tumor tissue compare normal tissue . This single center , non-randomized , open-label Phase II clinical study investigate efficacy tolerability albumin-bound paclitaxel plus nedaplatin patient advance , recurrent metastatic cervical cancer . About 30 patient receive 175-200 mg/m2 albumin-bound paclitaxel , 1 combine 80- 100 mg/m2 nedaplatin , 2 , every 3 week . At least 2 cycle complete patient , respond treatment , 4-6 cycle complete .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Cervical cancer , advance recurrent metastasis Measurable assessible tumor lesion Used ordinary paclitaxel platinum drug , 28 day Aged 1870 KPS score &gt; 60 point , expect survive 3 month Normal bone marrow function The function liver kidney obvious damage Normal function vital organs No brain metastases Patients agent sign inform consent Compliance , follow regularly Brain metastasis Serious complication Acute inflammatory response Combined tumor Pregnancy breastfeed woman Vertebral metastasis nerve compression symptom Large volume pleural effusion , pericardial effusion Other malignancy within five year Drug allergy Other chemotherapy contraindication The possibility pregnancy , willing contraception No measurement lesion Mental illness difficult control</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Advanced uterine cervical cancer</keyword>
</DOC>